Axial Spondyloarthritis & Hip Pain: Symptoms & Treatment

The increasing burden of axial spondyloarthritis (axSpA) extends beyond spinal inflammation, with new data highlighting a significant impact on hip health, particularly among Black American men. A recent retrospective analysis from a rheumatology clinic in Morocco reveals that radiographic hip involvement – detectable via imaging – affects nearly 14% of axSpA patients and is strongly correlated with more severe disease overall. This finding isn’t merely descriptive; it underscores a critical need for proactive hip monitoring and intervention in axSpA management, a facet often overshadowed by the focus on spinal symptoms.

Axial spondyloarthritis is a chronic inflammatory disease primarily affecting the spine, but it’s increasingly recognized as a systemic illness capable of impacting peripheral joints like the hips. The study, analyzing 137 patients followed between 2019 and 2023, used the Bath Ankylosing Spondylitis Radiology Hip Index (BASRI) to assess hip involvement. The finding that hip involvement can be unilateral or bilateral is important for clinicians to consider during examination and imaging. The Moroccan study’s prevalence (13.9%) is lower than some university hospital series, potentially reflecting differences in patient populations and access to advanced imaging. However, the consistent association with disease severity remains a key takeaway.

The observed link between hip involvement and uveitis is particularly noteworthy. Both conditions represent extra-articular manifestations of axSpA – meaning they affect areas outside the joints – and their co-occurrence suggests a more aggressive disease phenotype. This clustering of severe features highlights the importance of a holistic assessment of axSpA patients, extending beyond spinal symptoms to include a thorough evaluation for peripheral joint and ocular involvement.

The Forward Look

This research is likely to fuel a shift towards more aggressive monitoring of hip health in axSpA patients, particularly men with longer disease durations. We can anticipate increased utilization of BASRI scoring and routine hip imaging (X-rays or MRIs) as part of standard axSpA care. More importantly, the findings will likely prompt further investigation into the underlying mechanisms driving hip involvement in axSpA. Are there specific genetic or immunological factors that predispose certain individuals to hip disease? Understanding these mechanisms could pave the way for targeted therapies aimed at preventing or mitigating hip damage. Finally, given the observed disparities, future research should specifically focus on the prevalence and severity of hip involvement in diverse populations, including larger cohorts of Black American patients, to ensure equitable access to optimal care. The current study provides a crucial foundation for these next steps, moving beyond simply recognizing the problem to actively seeking solutions.